BSETrident Texofab LtdHighNeutral
Announced Thu, 29 May · 20:05 IST

Outcome of Board Meeting held on May 29, 2025 to consider and approve the financial result for the Quarter and year ended on March 31, 2025

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Trident Texofab's Board, on May 29, 2025, approved audited standalone financial results for FY ended March 31, 2025, with an unmodified opinion from statutory auditor Shah Kailash & Associates LLP. FY25 revenue from operations rose to Rs. 12,205.62 lakhs from Rs. 9,948.34 lakhs in FY24 (~22.7% growth), while profit after tax more than doubled to Rs. 251.01 lakhs (vs Rs. 107.98 lakhs). The company also converted 4,50,477 warrants into equity shares at Rs. 70 each, receiving Rs. 2.36 crore, which raised paid-up capital to Rs. 14.51 crore (1.45 crore shares). Additionally, M/s. Purushottam Khandelwal & Co. was appointed as Internal Auditor for FY 2025-26. Q4 FY25 revenue stood at Rs. 3,820.63 lakhs with PAT of Rs. 51.05 lakhs. Operating cash flow remained healthy at Rs. 695.89 lakhs.

Likely market impact

Strong FY25 performance with revenue and PAT both showing significant growth signals business expansion and improved profitability. The warrant conversion is mildly dilutive (issue price Rs. 70 vs current capital base), but the fresh capital strengthens the balance sheet. Overall positive for shareholders with no audit concerns raised.